parallel randomized trial
S003087
Type 2 diabetes (adults)S003087
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability CSII plus liraglutide | CSII insulin aspart and metformin 2000 mg daily; lifestyle: standard | 33 | 30 | |
| A2 | Standard care or no added treatment CSII | CSII insulin aspart and metformin 2000 mg daily; lifestyle: standard | 32 | 30 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability A1 | Standard care or no added treatment A2 |
|---|---|---|---|
| age | median (years) | 50.0 | 49.0 |
| age | q1 (years) | 42.5 | 42.5 |
| age | q3 (years) | 63.5 | 61.0 |
| bmi | mean (kg/m2) | 29.4 | 29.0 |
| bmi | sd (kg/m2) | 3.4 | 4.2 |
| diabetes duration | median (years) | 9.0 | 6.0 |
| diabetes duration | q1 (years) | 2.0 | 3.0 |
| diabetes duration | q3 (years) | 17.5 | 13.0 |
| established cvd | n | 9 | 6 |
| female | n | 3 | 7 |
| hba1c | median (percent) | 9.3 | 10.0 |
| hba1c | q1 (percent) | 8.5 | 8.8 |
| hba1c | q3 (percent) | 13.0 | 12.0 |
| insulin dose | median (U/kg/day) | 0.59 | 0.62 |
| insulin dose | q1 (U/kg/day) | 0.55 | 0.57 |
| insulin dose | q3 (U/kg/day) | 0.64 | 0.65 |
| sbp | mean (mmHg) | 140.0 | 135.3 |
| sbp | sd (mmHg) | 18.1 | 17.4 |
| uacr: microalbuminuria | n | 8 | 12 |
| weight | mean (kg) | 85.5 | 82.4 |
| weight | sd (kg) | 9.8 | 11.8 |
Results
11 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Body weight change in kilograms (diabetes) (3 lines; O02)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 2 | A1 | change | -2.5 kg | 0.5 | 30 | not stated; completers; R0019704:Results | |
| 2 | A2 | change | 0.2 kg | 1.1 | 30 | not stated; completers; R0019704:Results | |
| 2 | A2 vs A1 | md | 2.7 kg | not stated; completers; R0019704:Results |
Level 2 or 3 hypoglycemia (participants) (2 lines; O04)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 30 | not stated; completers; R0019704:Results | ||||
| A2 | events | 0 / 30 | not stated; completers; R0019704:Results |
Percent body weight change (3 lines; O10)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 2 | A1 | percent change | -2.93 percent | 30 | not stated; completers; R0019704:Results | ||
| 2 | A2 | percent change | 0.24 percent | 30 | not stated; completers; R0019704:Results | ||
| 2 | A2 vs A1 | md | 3.17 percent | not stated; completers; R0019704:Results |
Nausea (1 lines; O27A)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 9 / 30 | not stated; completers; R0019704:Methods |
Vomiting (1 lines; O27B)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 1 / 30 | not stated; completers; R0019704:Methods |
Diarrhea (1 lines; O27C)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 1 / 30 | not stated; completers; R0019704:Methods |